Glutathione (GSH)
Glutathione (GSH) scored 6.2 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Amino Acid.
Glutathione is the body's master antioxidant, a cysteine-bearing tripeptide that powers detoxification and redox balance. Oral supplements are bioavailability-limited: a single dose barely raises blood levels, though Richie 2015 found 6 months of 1,000 mg/day raised body stores 30 to 35 percent. Real human outcomes stay modest and route-dependent.
What is Glutathione (GSH)?
Glutathione is the body's master antioxidant, a small tripeptide built from glutamate, cysteine, and glycine that every cell uses to keep its internal chemistry in balance. It scores 6.2 out of 10, a worth-trying rating that reflects an honest split: the mechanism is foundational and the safety record is excellent, but the human outcome data for taking it as a supplement is modest, mixed, and heavily dependent on which form you use. Glutathione is the most abundant antioxidant inside your cells, sitting at concentrations a hundred times higher than in the blood, with the liver holding the largest reserve. It neutralizes reactive oxygen species directly and powers the detoxification enzymes that clear drugs and toxins.
The reason glutathione earns a measured score rather than a glowing one is bioavailability. When you swallow it, gut enzymes break most of it apart before it reaches your bloodstream, so a single dose barely moves blood levels. Chronic daily dosing can slowly raise body stores, and sublingual or liposomal forms perform better than plain capsules, but the gap between the marketing enthusiasm and the proven clinical benefit is real. The most reliable way to raise glutathione may not be glutathione at all, but its cysteine precursor.
Terminology
Glutathione comes wrapped in biochemistry shorthand, and a few terms change how you read the evidence. The most important distinction is between the molecule itself and its precursors: much of the strongest evidence is for N-acetylcysteine and the GlyNAC combination, not for swallowing glutathione directly. Knowing that the active and spent forms are recycled back and forth explains why the molecule is not simply used up. The terms below appear throughout this report.
- GSH: Glutathione in its active, reduced form, the working antioxidant molecule.
- GSSG: Glutathione disulfide, the spent oxidized form (two GSH joined), which the body recycles back to GSH.
- NAC: N-acetylcysteine, a cysteine-supplying precursor used to raise glutathione and the standard antidote for acetaminophen overdose.
- GlyNAC: A combination of glycine and N-acetylcysteine that supplies both amino acids needed to rebuild glutathione.
- Glutathione peroxidase (GPx): A selenium-dependent enzyme that uses glutathione to neutralize hydrogen peroxide and lipid peroxides.
- Glutathione-S-transferase (GST): A detoxification enzyme that attaches glutathione to toxins and drugs so the body can excrete them.
- Gamma-glutamylcysteine: The two-amino-acid intermediate formed in the first, rate-limiting step of glutathione synthesis.
- ROS: Reactive oxygen species, unstable oxygen molecules that damage cells and that antioxidants neutralize.
- Oxidative stress: An imbalance where reactive oxygen species outpace antioxidant defenses and cause cellular damage.
- Phase II detoxification: The conjugation stage of liver detox where toxins are bound to molecules like glutathione for excretion.
- Liposomal: A delivery form that wraps the compound in tiny fat bubbles to improve absorption.
- NAFLD: Non-alcoholic fatty liver disease, fat buildup in the liver not caused by alcohol.
- UPDRS: Unified Parkinson's Disease Rating Scale, the standard scoring of Parkinson symptom severity.
- Stevens-Johnson syndrome: A rare, severe, potentially fatal skin and mucous-membrane reaction, often drug-triggered.
How do you take Glutathione (GSH)?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 5 routes and 2 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral capsule or tablet (reduced glutathione) | Capsule, tablet, or powder | 250 to 1,000 mg/day | 250 to 2,000 mg/day |
| Sublingual | Dissolvable tablet or troche | 250 to 500 mg/day | 250 to 1,000 mg/day |
| Liposomal oral | Lipid-encapsulated liquid or capsule | 500 to 1,000 mg/day | 500 to 1,400 mg/day |
| Intravenous | Clinic infusion | 600 to 1,400 mg per session in research | 600 to 2,000 mg per session |
| Intranasal | Nasal spray | 300 to 600 mg/day in Parkinson trials | 300 to 600 mg/day |
Protocols
Tracked oral store-building Clinical
- Dose
- 1,000 mg/day
- Frequency
- Daily
- Duration
- 3 to 6 months
Mirrors the Richie 2015 high-dose arm. Pair with a baseline and follow-up marker because the benefit is gradual and not universal.
Precursor-first approach Clinical
- Dose
- N-acetylcysteine 600 to 1,200 mg/day
- Frequency
- Daily
- Duration
- Ongoing or cycled
A cheaper, better-established way to raise glutathione by supplying the rate-limiting cysteine. Consider before or instead of oral glutathione.
How this score is calculated →
What are the benefits of Glutathione (GSH)?
Upside contribution: 1.73
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.6 | 0.650 | |
| Breadth | 15% | 3.0 | 0.450 | |
| Evidence | 25% | 2.8 | 0.700 | |
| Speed | 10% | 2.5 | 0.250 | |
| Durability | 10% | 2.3 | 0.230 | |
| Bioindividuality | 15% | 3.0 | 0.450 | |
| Total | 2.730 |
Upside Rationale
The upside of glutathione comes from a foundational mechanism and a clean safety record rather than from a thick stack of outcome trials. The strongest human evidence is Richie 2015, a 6-month double-blind RCT showing oral dosing can raise body stores, but the boundary condition is everything: the benefit is slow, route-dependent, and clearest in people who are depleted or under oxidative load. This is a molecule whose biology is beyond dispute and whose supplemental payoff is genuine but bounded by how little of it survives digestion.
Efficacy (2.6/5.0): Real-world clinical magnitude is modest, which is why efficacy sits below the midpoint. The clearest outcome signal is hepatic: Honda 2017 lowered ALT from 68.9 to 58.1 IU/L over 4 months in 34 fatty-liver patients, a real but single-arm result. Against that, the controlled Parkinson trials were null and the skin-whitening RCT missed significance. Richie 2015 proved oral dosing can raise stores 30 to 35 percent, but a surrogate marker rising is not the same as a demonstrated clinical benefit. The honest efficacy read is a quiet, population-specific effect, strongest in depleted or fatty-liver users, not a broad performance enhancer.
Breadth of Benefits (3.0/5.0): The mechanism touches many systems, which earns a middling breadth score. Glutathione supports the liver through Phase II conjugation, the immune system through lymphocyte and natural-killer-cell function (cytotoxicity more than doubled in Richie 2015), and general redox balance everywhere. But mechanistic reach is not the same as proven endpoints. The systems with actual human signal narrow quickly to liver enzymes and a few oxidative and immune markers. Cognition, cardiovascular, and metabolic claims rest mostly on precursor studies rather than glutathione itself, so the breadth is real in theory and thin in confirmed practice.
Evidence Quality (2.8/5.0): Evidence is genuinely mixed rather than thin. There is one good 6-month double-blind RCT on body stores, an open-label fatty-liver pilot, small immune pilots, and a crossover study comparing routes. But the controlled outcome trials that matter most are null: Hauser 2009 and Mischley 2017 both failed to beat placebo in Parkinson disease, and Weschawalit 2017 missed significance on pigmentation. This is not an RCT-absence penalty; the trials exist and several came back modest or null. The pathway's most convincing evidence belongs to the precursor N-acetylcysteine, not to glutathione supplementation.
Speed of Onset (2.5/5.0): Oral glutathione works slowly. The body-store gains in Richie 2015 accumulated over 6 months, and the fatty-liver enzyme drop was measured at 4 months. Intravenous glutathione spikes plasma levels within minutes but clears with a roughly 14-minute half-life per Aebi 1991, so even the fast route is fleeting. There is no acute felt effect to chase, which makes a baseline-and-reassess approach essential.
Durability (2.3/5.0): Benefits depend on continued dosing. Because the body tightly regulates glutathione synthesis and the supplement washes out, stopping returns stores toward baseline rather than locking in a gain. The IV spike disappears in minutes, and the oral store increase requires sustained intake to maintain. This is a maintenance intervention, not a one-time correction, which lowers the durability score.
Bioindividuality Upside (3.0/5.0): Response varies widely, which is a genuine upside for the right person. Adults who are glutathione-depleted, older, or carrying fatty liver or high oxidative-stress burden are the likeliest responders, mirroring where Honda 2017 and the GlyNAC precursor trials found effects. Healthy, well-nourished users may notice little. Route is the other big individual variable: a non-responder on plain capsules can become a responder on sublingual or liposomal forms, as the crossover comparison in Schmitt 2015 suggested. This responder heterogeneity rewards self-tracking.
What are the risks & downsides of Glutathione (GSH)?
Downside contribution: 0.75 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 1.6 | 0.480 | |
| Side effects | 15% | 1.7 | 0.255 | |
| Cost | 5% | 2.2 | 0.110 | |
| Effort | 5% | 2.0 | 0.100 | |
| Opportunity | 5% | 2.4 | 0.120 | |
| Dependency | 15% | 1.3 | 0.195 | |
| Reversibility | 25% | 1.3 | 0.325 | |
| Total | 1.585 | |||
| Harm subtotal × 1.4 | 1.757 | |||
| Opportunity subtotal × 1.0 | 0.330 | |||
| Combined downside | 2.087 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.747 |
Downside Rationale
The downside of glutathione is mild and dominated by opportunity cost rather than harm. The molecule itself is one of the safest things you can swallow, with no dependency, easy reversibility, and benign side effects. The dominant practical concern is that a cheaper, better-evidenced precursor may do the job better, and the only serious safety signal, injuries from unregulated IV injections, is a sourcing problem rather than a property of the molecule. Per the intrinsic-baseline rule, the report scores correctly-sourced, correctly-dosed oral glutathione, not contaminated clinic injections.
Safety Risk (1.6/5.0): Oral and inhaled glutathione are benign. Trials up to 6 months reported no significant adverse events, and the molecule is endogenous, so the body already manages it. The serious harms, including Stevens-Johnson syndrome and an endotoxin-contamination cluster documented by the US FDA in 2019, all trace to unregulated injectable use and adulterated product, captured in the Philippine FDA advisory. Those are extrinsic sourcing and misuse risks, not intrinsic properties of correctly-sourced oral glutathione, so they belong in a Verdict caveat rather than inflating this dimension.
Side Effect Profile (1.7/5.0): Side effects are minimal and reversible. The most common report across oral trials is occasional mild digestive upset, and even that is uncommon. There is no consistent pattern of headaches, sleep disruption, or other nuisance effects in the supplement-dose literature. The benign side-effect profile is one of glutathione's genuine strengths.
Financial Cost (2.2/5.0): Cost is low for plain oral glutathione, roughly $10 to $25 per month, but rises sharply for the better-absorbed forms. Liposomal products cost more per dose, and clinic IV sessions are far more expensive while delivering only a brief spike. The cheapest effective option for raising glutathione is often the precursor rather than glutathione itself.
Time/Effort Burden (2.0/5.0): Effort is modest. The protocol is a daily capsule or sublingual tablet, with the only real decision being which route to use. There is no cycling requirement or complex timing, though committing to a multi-month trial with before-and-after markers takes some discipline given the slow onset.
Opportunity Cost (2.4/5.0): This is the most meaningful downside. For the specific goal of raising glutathione, N-acetylcysteine is cheaper and better established, and the GlyNAC combination has more compelling aging-related data per Kumar 2023. Money and attention spent on poorly-absorbed oral glutathione could go to the precursor pathway or to foundational antioxidants with stronger outcome evidence. Glutathione is not a wasted slot, but it is rarely the highest-leverage one.
Dependency/Withdrawal (1.3/5.0): There is no dependency or withdrawal. Glutathione is made and regulated endogenously, and stopping the supplement simply returns stores toward your natural baseline with no rebound or adaptation syndrome.
Reversibility (1.3/5.0): Reversibility is clean. You can stop at any time with no taper and no lasting change, since the supplement adds to a pool the body already controls. This is among the easiest interventions to discontinue.
Is Glutathione (GSH) worth it?
Glutathione is a 6.2 out of 10, worth trying for the right person and easy to overrate for everyone else. The practical verdict is to treat it as a targeted, tracked experiment rather than a blanket wellness staple. The people most likely to benefit are those with measured glutathione depletion, fatty liver, or a high oxidative-stress burden who will pick an absorbable route and watch a specific marker. The people most likely to waste money are healthy users swallowing plain capsules expecting dramatic effects, and anyone chasing skin whitening, where the evidence is weak and the injectable route is dangerous. The score tier is justified by a foundational mechanism and excellent safety pulling up against modest, mixed clinical outcomes and a cheaper precursor alternative pulling down.
✅ Best for: Adults with documented glutathione depletion or high oxidative-stress burden who will track a redox or inflammatory marker; people with non-alcoholic fatty liver disease willing to monitor ALT over 3 to 4 months, the population with the clearest signal in Honda 2017; older adults exploring the aging-redox angle who understand the strongest data is for the GlyNAC precursor; experimenters willing to use a sublingual or liposomal form rather than plain capsules to overcome poor absorption; anyone who would otherwise reach for an unproven antioxidant and prefers a benign, well-understood molecule with a clean stop.
❌ Avoid if: You expect a dramatic acute effect, because oral glutathione works slowly and subtly; you are pursuing skin lightening, where the oral evidence missed significance and the injectable route is unapproved and linked to Stevens-Johnson syndrome and contamination; you would source injectable glutathione from a non-medical or skin-whitening clinic, the one genuinely risky path; you want the most cost-effective way to raise glutathione, in which case N-acetylcysteine is the better-evidenced and cheaper precursor; or you are already well-nourished and antioxidant-replete and would notice nothing.
What is Glutathione (GSH) best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Antioxidant / Oxidative Stress: 6.5/10
Score: 6.5/10Antioxidant support is glutathione's home turf and earns 6.5/10, the highest subrating, because the mechanism is foundational rather than speculative: glutathione is the cell's master redox buffer and the cofactor for glutathione peroxidase. The catch is translation. Richie 2015 showed 6 months of 1,000 mg/day lowered the oxidized-to-reduced glutathione ratio and raised stores 30 to 35 percent, but Allen 2011 found no change in F2-isoprostanes or 8-OHdG over 4 weeks. Duration and route decide the result. Sublingual moved the redox ratio in a crossover study where plain oral did not. The honest read: glutathione reliably is an antioxidant, but raising it by mouth to a degree that shifts oxidative-stress endpoints is slow and route-sensitive.
Liver / Detoxification: 6.0/10
Score: 6.0/10The liver case scores 6.0/10 because the liver holds the body's highest glutathione concentration and runs the Phase II conjugation that glutathione enables. The most direct human signal is Honda 2017, an open-label NAFLD pilot where oral glutathione at 300 mg/day for 4 months lowered ALT from 68.9 to 58.1 IU/L (p=0.014) alongside drops in triglycerides and ferritin. That is a real, decision-relevant signal, but it is single-arm with no placebo, so confidence is capped. The strongest detoxification outcome in all of medicine sits one step away: the precursor N-acetylcysteine restores hepatic glutathione and reverses acetaminophen poisoning per Prescott 1977. That validates the pathway even though it is not glutathione supplementation itself.
Immune Function: 5.5/10
Score: 5.5/10Immune support scores 5.5/10 on a mechanism-plus-small-trial basis. Glutathione is essential to lymphocyte and natural-killer-cell function, and Richie 2015 reported natural-killer-cell cytotoxicity more than doubled at 3 months in the high-dose arm. A liposomal pilot pointed the same direction with larger immune-marker swings, but it was uncontrolled with only 12 participants. The signal is biologically coherent and the direction is consistent, yet the trials are small and the endpoints are laboratory measures rather than fewer infections or clinical outcomes. This is a use case where glutathione is plausible and lightly supported, best judged by tracking how you actually feel through a cold season rather than by the mechanism alone.
Metabolic Health: 5.2/10
Score: 5.2/10Metabolic health lands at 5.2/10, carried mostly by the precursor and liver-adjacent data rather than by glutathione monotherapy. Honda 2017 saw triglycerides and non-esterified fatty acids fall alongside ALT in fatty-liver patients, which is metabolically relevant. The GlyNAC trials from the Sekhar group reported improvements in insulin resistance and mitochondrial function in older adults, but those used glycine plus N-acetylcysteine, not glutathione, and came from a single laboratory. Glutathione supplementation on its own has no large metabolic outcome trial. The fair conclusion is that the glutathione pathway is metabolically active in depleted or fatty-liver populations, while healthy metabolic users should expect little from oral glutathione by itself.
Anti-Inflammatory: 5.0/10
Score: 5.0/10Anti-inflammatory effects score 5.0/10 as a reasonable but indirect inference. Glutathione status modulates redox-sensitive inflammatory signaling, and the liposomal pilot reported a 35 percent drop in the oxidative marker 8-isoprostane. But no glutathione trial has shown consistent reductions in core inflammatory markers like hs-CRP or interleukin-6 as a primary, replicated endpoint. The effect is mechanistically credible and tied to oxidative-stress reduction rather than direct cytokine suppression. Someone targeting inflammation should treat glutathione as a background redox support, define one marker such as hs-CRP before starting, and judge the molecule by that number rather than by the antioxidant theory it rests on.
| Use Case | Score | Summary |
|---|---|---|
| ○ Neuroprotection Primary | 4.5 | Neuroprotection is the marquee research target and the clearest cautionary tale, scoring 4.5/10. Brain glutathione is depleted in Parkinson disease, which inspired multiple trials. The uncontrolled Sechi 1996 IV series reported a 42 percent disability decline, but every controlled study since has been null: Hauser 2009 found IV glutathione no better than placebo, and Mischley 2017 found intranasal glutathione improved versus baseline but not versus placebo. The mechanism is real and the depletion is documented, yet the controlled human evidence does not support a protective claim. This is exactly where surrogate logic outran outcomes. |
| ○ Longevity / Lifespan | 4.5 | Longevity scores 4.5/10. Glutathione decline tracks aging, and the GlyNAC work from the Sekhar group reported reversal of several aging hallmarks in older adults, but that is glycine plus N-acetylcysteine and comes from one small single-lab program. Glutathione supplementation itself has no human lifespan or healthspan outcome trial. The molecule is a plausible piece of the aging-redox puzzle and the precursor data is intriguing, but plausibility is not proof. Anyone pursuing glutathione for longevity is making a mechanistic bet, and the better-supported version of that bet currently runs through cysteine precursors rather than through swallowing glutathione directly. |
| ○ Energy / Fatigue | 4.5 | Energy and fatigue score 4.5/10 on subjective and indirect grounds. People with high oxidative-stress burden sometimes report better energy when glutathione status improves, and fatigue is the most common positive anecdote, but there is no dedicated fatigue RCT for glutathione supplementation with a clean placebo comparison. Mitochondrial function improved in the GlyNAC precursor trials, which is energy-relevant, yet that is not glutathione alone. Treat any energy benefit as a personal experiment: track a simple daily 1-to-5 energy rating against a baseline, and stop if nothing shifts within a couple of months of consistent dosing on an absorbable route. |
| ○ Skin / Beauty | 4.0 | Skin scores 4.0/10 despite being glutathione's most-marketed use, because the evidence does not match the hype. Weschawalit 2017, the headline oral skin RCT, found the melanin index only trended lower without reaching significance; the one significant skin finding was reduced wrinkles. A review of three RCTs concluded glutathione is not beneficial enough as a skin-whitening agent with no lasting effect. Injectable glutathione for lightening is unapproved and warned against. The honest verdict: a faint, inconsistent cosmetic signal at best, not the dramatic whitening that drives sales, and the injectable route carries real risk for an unproven benefit. |
| ○ Geriatric / Aging Population | 4.0 | Older adults are the population where glutathione decline is documented and the precursor trials showed effects, but glutathione monotherapy is unproven in this group, scoring 4.0/10. |
| ○ Recovery / Repair | 3.5 | Recovery support is indirect, scoring 3.5/10. Reduced oxidative damage could plausibly aid recovery, but glutathione lacks dedicated exercise-recovery trials with meaningful endpoints. |
| ○ Stress / Resilience | 3.5 | Oxidative-stress reduction is mechanistically adjacent to physiological stress resilience, but there is no direct human resilience or HPA-axis trial for glutathione, so it scores 3.5/10. |
| ○ Healthspan | 3.5 | Healthspan rests on the same precursor-driven aging data as longevity and is not demonstrated for glutathione supplementation itself, scoring 3.5/10. |
| ○ Mitochondrial | 3.5 | Mitochondrial benefit appears in the GlyNAC precursor trials, not in glutathione monotherapy, so the direct case is weak at 3.5/10. |
| ○ Respiratory | 3.5 | Inhaled glutathione has been studied in cystic fibrosis but missed its primary endpoint; the respiratory case is real but unproven, scoring 3.5/10. |
| ○ Cognition / Focus | 3.0 | No cognition or focus RCT supports glutathione supplementation; the Parkinson trials targeted motor symptoms and were null on controlled endpoints. Scores 3.0/10. |
| ○ Cardiovascular | 3.0 | Endothelial and lipid effects appear indirectly through precursor trials, not glutathione supplementation, so the direct cardiovascular case is thin at 3.0/10. |
| ○ Heavy Metal / Toxin Burden | 3.0 | Glutathione conjugates some toxins via Phase II enzymes, but there is no clinical chelation outcome evidence, so it scores 3.0/10 on mechanism alone. |
| ○ Blood Sugar / Glycemic Control | 3.0 | Glycemic effects appear only in the GlyNAC precursor data, not in glutathione monotherapy, scoring 3.0/10. |
| ○ Fertility (Male) | 3.0 | Antioxidant support of sperm parameters is plausible and lightly studied for the broader thiol pathway, but glutathione-specific human fertility evidence is limited, scoring 3.0/10. |
Frequently Asked Questions
What does glutathione actually do in the body?
Glutathione is the cell's master antioxidant, a tripeptide of glutamate, cysteine, and glycine that maintains redox balance. It directly scavenges reactive oxygen species, supplies the enzyme glutathione peroxidase to neutralize peroxides, and drives glutathione-S-transferase Phase II detoxification in the liver, where concentrations are highest. It also helps regenerate vitamins C and E. The cysteine thiol does the chemical work, and the body recycles the spent oxidized form back to active glutathione using NADPH, so the molecule is continuously reused rather than consumed once.
Is oral glutathione actually absorbed, or is it a waste of money?
Oral glutathione is poorly absorbed in a single dose, the most honest weakness of the supplement. Witschi 1992 gave roughly 3 grams by mouth and saw no rise in plasma glutathione, and classical estimates put oral bioavailability below 1 percent because gut enzymes hydrolyze it. The nuance is duration: Richie 2015 found 6 months of daily dosing raised body stores 30 to 35 percent, likely by recycling the freed amino acids. Sublingual and liposomal forms perform better than plain capsules for moving redox markers.
How much glutathione should I take and which form is best?
The clinical range is 250 to 1,000 mg/day, with the strongest store-raising data at 1,000 mg/day over months in Richie 2015. Form matters more than dose: a crossover study found sublingual glutathione raised the reduced-to-oxidized ratio where plain oral capsules did not, and liposomal showed promise in a small pilot. Many people get more reliable results by supplying the precursor instead, taking N-acetylcysteine at 600 to 1,200 mg/day, which is cheaper and better established at raising glutathione.
Does glutathione really lighten or whiten skin?
The skin-lightening claim is weak and oversold. The headline oral RCT, Weschawalit 2017, found the melanin index only trended lower without reaching significance, and a review of three trials concluded glutathione is not beneficial enough as a whitening agent with no lasting effect. Injectable glutathione for lightening is not FDA-approved, and the Philippine FDA warns of liver, kidney, and Stevens-Johnson risks. Treat any cosmetic benefit as faint and inconsistent, and avoid unregulated injections entirely.
Is glutathione safe to take long term?
Oral and inhaled glutathione are remarkably safe, with trials up to 6 months reporting no significant adverse events beyond occasional mild digestive upset. The serious risks cluster entirely around unregulated injectable use: documented cases include Stevens-Johnson syndrome, and the US FDA found endotoxin contamination in compounded injectables that harmed 7 patients. That harm reflects contaminated or improperly sourced product, not the molecule itself. Taken by mouth from a reputable source, glutathione has one of the cleaner safety records in the supplement world.
Should I take glutathione or NAC to raise my glutathione?
For raising glutathione, the precursor route is often the smarter buy. N-acetylcysteine supplies cysteine, the rate-limiting building block, and is the proven antidote that restores hepatic glutathione in acetaminophen overdose per Prescott 1977. It is cheaper and better established than oral glutathione. The combination GlyNAC, glycine plus N-acetylcysteine, showed promising aging-related effects in Kumar 2023. Direct glutathione makes more sense in a sublingual or liposomal form when you specifically want the intact molecule.
How long does glutathione take to work?
Expect weeks to months, not days, on oral dosing. The body-store gains in Richie 2015 emerged over a 6-month course, and the fatty-liver enzyme drop in Honda 2017 was measured at 4 months. Intravenous glutathione spikes plasma levels within minutes but clears with a roughly 14-minute half-life, so the spike is fleeting. Because the meaningful changes are gradual, set a baseline marker and reassess after about 3 months rather than chasing an immediate sensation.
Does glutathione help fatty liver disease?
Fatty liver is glutathione's most promising clinical target, though the evidence is still early. Honda 2017 gave oral glutathione 300 mg/day for 4 months to 34 patients with non-alcoholic fatty liver disease and saw ALT fall from 68.9 to 58.1 IU/L (p=0.014), with triglycerides and ferritin also dropping. The catch is that this was an open-label single-arm pilot with no placebo group, so the result is suggestive rather than confirmed. No placebo-controlled glutathione trial in fatty liver has been published, which keeps confidence moderate.
What could change Glutathione (GSH)'s score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The most plausible update that would move this score is a well-run, placebo-controlled outcome trial of an absorbable glutathione form in a depleted or fatty-liver population. A positive result would lift efficacy and evidence together and push glutathione into the strong-recommend tier; a continued string of null controlled trials, as already seen in Parkinson disease, would pull it back toward neutral. The dimensions most likely to move first are efficacy and evidence, since safety, dependency, and reversibility are already near their floors and unlikely to change.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| A placebo-controlled RCT confirms ALT and metabolic benefit in fatty liver | Efficacy 2.6 to 3.6, evidence 2.8 to 3.6 | 7.1 / 10 💪 Strong recommend |
| Liposomal or sublingual forms prove clearly superior absorption with outcome data | Efficacy 2.6 to 3.2, bioindividuality 3.0 to 3.6 | 6.8 / 10 👍 Worth trying |
| GlyNAC-style outcomes are replicated and apply to glutathione directly | Efficacy 2.6 to 3.2, breadth 3.0 to 3.6 | 6.8 / 10 👍 Worth trying |
| More controlled trials come back null like the Parkinson studies | Efficacy 2.6 to 2.2, evidence 2.8 to 2.4 | 5.6 / 10 ⚖️ Neutral |
| A specific intrinsic safety signal emerges for oral use | Safety 1.6 to 2.6 | 5.5 / 10 ⚖️ Neutral |
| Better-absorbed forms still fail to raise meaningful clinical endpoints | Efficacy 2.6 to 2.0, evidence 2.8 to 2.2 | 5.3 / 10 ⚖️ Neutral |
Key Evidence Sources
- Witschi A et al. 1992 - The systemic availability of oral glutathione, European Journal of Clinical Pharmacology. Classic single-dose study, n=7: ~3 g oral glutathione did not raise plasma glutathione, cysteine, or glutamate over 270 minutes.
- Allen J & Bradley RD 2011 - Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers, Journal of Alternative and Complementary Medicine. RCT, n=40, 500 mg twice daily for 4 weeks: no significant change in oxidative-stress biomarkers (F2-isoprostanes p=0.38).
- Richie JP Jr et al. 2015 - Randomized controlled trial of oral glutathione supplementation on body stores of glutathione, European Journal of Nutrition. 6-month double-blind RCT, n=54: 1,000 mg/day raised glutathione stores 30 to 35 percent and natural-killer cytotoxicity more than doubled.
- Schmitt B et al. 2015 - Effects of N-acetylcysteine, oral glutathione and a novel sublingual form of glutathione on oxidative stress markers: a comparative crossover study, Redox Biology. Crossover study, n=20: plain oral glutathione did not raise the reduced-to-oxidized ratio, but the sublingual form did (p=0.002).
- Sinha R et al. 2018 - Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function, European Journal of Clinical Nutrition. Uncontrolled pilot, n=12: liposomal glutathione raised blood stores and immune markers, but small and without a control arm.
- Honda Y et al. 2017 - Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease, BMC Gastroenterology. Open-label pilot, n=34: oral glutathione 300 mg/day for 4 months lowered ALT from 68.9 to 58.1 IU/L (p=0.014).
- Sechi G et al. 1996 - Reduced intravenous glutathione in the treatment of early Parkinson's disease, Progress in Neuro-Psychopharmacology and Biological Psychiatry. Open-label series, n=9: IV glutathione associated with a 42 percent disability decline, but uncontrolled and hypothesis-generating only.
- Hauser RA et al. 2009 - Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease, Movement Disorders. RCT, n=21: IV glutathione improved UPDRS only 2.8 units more than placebo (p=0.32), effectively null on the controlled endpoint.
- Mischley LK et al. 2017 - Phase IIb study of intranasal glutathione in Parkinson's disease, Journal of Parkinson's Disease. RCT, n=45: intranasal glutathione improved within-group UPDRS but neither active arm beat placebo.
- Weschawalit S et al. 2017 - Glutathione and its antiaging and antimelanogenic effects, Clinical Cosmetic and Investigational Dermatology. RCT, 250 mg/day for 12 weeks: melanin index only trended lower without significance; the one significant skin finding was reduced wrinkles.
- Sitohang IBS & Ninditya S 2020 - Systemic glutathione as a skin-whitening agent in adult, Dermatology Research and Practice. Review of 3 RCTs concluded glutathione is not beneficial enough as a skin-whitening agent and shows no long-lasting effect.
- Prescott LF et al. 1977 - Treatment of paracetamol poisoning with N-acetylcysteine, The Lancet. Landmark trial: N-acetylcysteine restores hepatic glutathione and prevents liver failure in acetaminophen overdose, the strongest glutathione-pathway outcome.
- Kumar P et al. 2023 - Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency and aging hallmarks: a randomized clinical trial, Journals of Gerontology Series A. 16-week RCT, n=24 older adults: GlyNAC corrected glutathione deficiency and improved oxidative stress and physical function. Related precursor combination, single-lab.
- Aebi S et al. 1991 - High-dose intravenous glutathione in man: pharmacokinetics and effects on cysteine in plasma and urine, European Journal of Clinical Investigation. Pharmacokinetics, n=10: IV glutathione raised plasma total glutathione to 823 micromol/L but with a 14.1 minute half-life, so the spike is brief.
- Philippine FDA Advisory No. 2019-182 - Unsafe use of glutathione as skin lightening agent. Regulatory warning: no approved injectable glutathione for skin lightening; risks include liver, kidney, nervous-system toxicity and Stevens-Johnson syndrome.
What does the evidence say about Glutathione (GSH)?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Witschi 1992, Richie 2015, Allen 2011, Honda 2017, Hauser 2009, Mischley 2017, Weschawalit 2017, Prescott 1977
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Prescott 1977
Holistic Evidence for Glutathione (GSH)
The modern and historical lenses agree on a useful split: the glutathione system is genuinely vital and the precursor pathway has a proven life-saving clinical record, while direct glutathione supplementation has a thinner, more route-dependent, and more modest outcome base than its marketing suggests.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- ALT Pre | Expected Watch Post | Expected Down
- GGT During | Expected Watch
- hs-CRP During | Expected Down
Pulse Dimensions to Watch
- Energy During | Expected Up | Secondary
- Body During | Expected Up | Secondary
Subjective Signals (Daily Voice Card)
- Daily energy and post-exertion recovery Scale 1-5 | During | Expected Up
- Skin clarity or tone, if that is the goal Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Any rash, blistering, or mucous-membrane sores after IV glutathione: stop and seek care, this can signal Stevens-Johnson syndrome.
- Sourcing injectable glutathione from a non-medical or skin-whitening clinic: contamination and serious adverse events have been documented.
📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.730 − 0.747 = 0.983
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.983 / 4.00) × 5 = 6.2 / 10
